JBIO Jade Biosciences
Price Chart
Executive Summary
Jade Biosciences announced the first participant has been dosed in a Phase 1 clinical trial of JADE201, a half-life extended, afucosylated anti-BAFF-R monoclonal antibody for autoimmune diseases. Interim data is expected in 2027, so no near-term catalyst is present.
Actionable Insight
No stock-moving data provided; focus remains on JADE101 Phase 2 data in IgA nephropathy and any future pipeline updates. Interim JADE201 results are years away, so near-term price action likely driven by broader market sentiment and other pipeline catalysts.
Key Facts
- First participant dosed in FIH Phase 1 trial of JADE201
- JADE201 targets BAFF-R with enhanced effector function and extended half-life
- Interim Phase 1 data expected in 2027
- Preclinical data showed dose-dependent BAFF-R occupancy and sustained B cell depletion
Financial Impact
No financial data disclosed; event is operational milestone with no direct revenue impact.
Risk Factors
- Phase 1 trial may fail to demonstrate safety or efficacy
- Competitors with similar B cell depletion therapies
- Cash burn with no near-term revenue
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301441 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
7d ago
|
Press Release
| $16.91 awaiting T+1 | awaiting T+1 | — | $15.34 (+9.28%) |
|
Jun 4, 2026
8d ago
|
8-K
| $17.52 awaiting T+1 | awaiting T+1 | — | $15.34 (+12.44%) |
|
Jun 4, 2026
8d ago
|
424B5
| $17.52 awaiting T+1 | awaiting T+1 | — | $15.34 (+12.44%) |
|
Jun 4, 2026
9d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.91% | $15.34 (+13.53%) |
|
Jun 3, 2026
9d ago
|
424B5
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $15.34 (+13.53%) |
|
Jun 3, 2026
9d ago
|
Press Release
| $17.74 $16.94 | ▲ +4.51% | ▲ +1.94% | $15.34 (+13.53%) |
|
Jun 1, 2026
11d ago
|
8-K
| $18.59 $17.75 | ▼ −4.52% | ▼ −4.66% | $15.34 (−17.48%) |
|
May 26, 2026
17d ago
|
Press Release
| $21.50 $20.84 | ▼ −3.07% | ▼ −3.62% | $15.34 (−28.65%) |
|
May 18, 2026
26d ago
|
EFFECT
| $22.01 $21.88 | ▲ +0.59% | ▼ −0.06% | $15.34 (+30.30%) |
|
May 7, 2026
5w ago
|
S-3
| $25.81 $24.86 | ▲ +3.68% | ▲ +3.91% | $15.34 (+40.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access